1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Concert Looks To Phase III In Alopecia Areata, Ahead Of Pfizer’s JAK Inhibitor

 
• By Joseph Haas

Concert believes its deuterated form of ruxolitinib has a better overall profile in alopecia areata than Pfizer’s JAK3 inhibitor. The company is planning to meet with the FDA to plan a Phase III program early in 2020.

Desperate Young Man Touching His Bald Patches - Image
Concert hopes to bring the first drug therapy for alopecia areata to market

With a full dataset now illustrating success for a deuterated formulation of ruxolitinib in alopecia areata, Concert Pharmaceuticals Inc. continues to believe its selective JAK1/2 inhibitor is on pace to get to market first in the unmet medical need, ahead of Pfizer Inc.’s competing Phase II candidate, selective JAK3 inhibitor PF-06651600.

Concert unveiled new data from its Phase II dose-ranging study of CTP-543 on 3 September, showing that a 12mg twice-daily dose met statistical significance compared to placebo by achieving a 50% or greater change from baseline at 24 weeks on the Severity of Alopecia Tool (SALT). In March, it reported that an 8mg twice-daily dose met statistical significance on this endpoint, while a 4mg twice-daily dose did not

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes

 
• By Sushmita Panda

Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

 
• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from R&D

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 
• By Andrew McConaghie

Shares are hit as German conglomerate lowers revenue forecast.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.